New Drug Keeps The Sleep-Deprived Sharp

Want a new drug? How about a new stock in a company with a new drug? How about both? Then you want to buy stock in Cortex Pharmaceuticals, and you want to score some CX717, the newest member of the class of drugs know as ampakines. The BBC reports that research (partially funded by DARPA) at Wake Forest University shows that CX717 prolongs the action of glutamate, allowing more effective communication between brain cells, and persuading the brain to maintain peak performance despite extreme sleep deprivation. And while it’s true that the brains tested at Wake Forest belonged to monkeys, researchers at Cortex report similarly impressive results on sleep-deprived humans. Wait, there’s more: the drug did not appear to be
linked to side effects such as hyperactivity, distorted thinking or
extended wakefulness. Very promising. Even if he can’t afford the stock, Geezer is counting on significant improvement in tennis games played after a long night on the town. Read more.